TNF and rheumatoid arthritis: TCZ was approved in Europe in 2009 for the treatment of moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF) antagonists [2].